Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Ajinomoto claims new acetyl-CoA carboxylase inhibitors for obesity, diabetes, etc.

Sep. 3, 2003

Prolonged pharmacokinetic profile reported for the novel GLP-1 analogue CJC-1131

Sep. 3, 2003

Inhibition of vasopeptidase with AVE-7688 reduces kidney damage in ZDF rats

Sep. 3, 2003

Renoprotective effects of magnesium lithospermate B in diabetic OLETF rats

Sep. 3, 2003

FDA grants orphan drug designation for Fidelin

Sep. 2, 2003

MacroChem expands phase II Topiglan trial into U.S.

Sep. 2, 2003

Squalene synthase inhibitor TAK-475 may have therapeutic potential in dyslipidemia

Sep. 2, 2003

New dosage strengths approved for Avandamet

Sep. 1, 2003

Lilly presents new melanocortin MC4 agonists in a recent patent

Sep. 1, 2003

LY-333531 reduces diabetic hyperalgesia

Sep. 1, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...